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Abstracts / Osteoarthritis and Cartilage 22 (2014) S7–S56S267.1. One-sample t-statistic maps were calculated to describe task-
related activations, and ANOVA (SPM Full Factorial repeated meas-
urements within groups and independent between groups) was used
to identify group by session treatment interaction effects and to
compare groups and sessions. The main outcome measurement was
attenuation of the response evoked by knee painful stimulation in
the pain-processing brain system.
Results: Patients receiving CS showed a tendency to report reduced
subjective pain after treatment during patella pressure test (p¼0.077),
but no signiﬁcant group by session interaction was demonstrated. fMRI
of patella pain, showed a larger activation reduction in the CS group
than in placebo in a posterior mesencephalon region including the
periaqueductal gray (PAG). The entire PAG cluster (238 voxels) with
signiﬁcant interaction showed a pre>post-treatment difference at
p<0.05 (peak difference at x¼-4, y¼-40, z¼-16; t¼2.4, p¼0.01). In this
paired analysis, the CS group showed signiﬁcant activation reduction
in the primary somatosensory cortex (including the cortical repre-
sentation of the leg) and extending to the primary motor cortex and
posterior supplementary motor area. Group by session interaction
consistently revealed a tendency for this cortical change to be larger in
the CS than in placebo (peak interaction x¼2, y¼-6, z¼72; t¼2.96,
p¼0.002 and 43 voxels-subthreshold- with p<0.01) (Figure 1). No
effects of CS were detected using the knee interline pressure test.
Conclusions: The study succeeded in the primary objective as a sig-
niﬁcant effect was demonstrated showing attenuation of brain response
to painful pressure in key regions of the pain-processing network using
the patella test.
Despite knee medial interline is one of the most tenders points in
patients with knee osteoarthritis, pressure on this site may generate
pain from damage or sensitization in a variety of structures. The
pain generated by pressing down the patella surface, in contrast, is
probably less complex, and may be more selectively related to
sensitization processes in the bone and the junction between the
bone and cartilage as a result of erosion in the patella and femoral
cartilages. The observed positive treatment effect of CS is consistent
with the known CS action on cartilage protection due to chon-
drocyte regeneration. fMRI was able to objectify CS effects on brain
response to knee pressure painful stimulation, yielding further
support to the utility of fMRI to objectify treatment effects on OA
pain.
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A SINGLE CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-
CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND
SAFETY OF INTRA-ARTICULAR ONABOTULINUMTOXINA AS
TREATMENT FOR OSTEOARTHRITIS KNEE PAIN: RESULTS FROM
THE EXPERIMENTAL PAIN MODELS
L. Arendt-Nielsen y, G.-L. Jiang z, R. DeGryse z, C.C. Turkel z. yAalborg
Univ., Sch. of Med., Ctr. for Sensory-Motor Interaction, Aalborg E,
Denmark; zAllergan, Inc., Irvine, CA, USA
Purpose: Peripheral and central sensitization can worsen knee
osteoarthritis (OA) pain. Focally administered onabotulinumtoxinA
(onabotA) has caused analgesia via disruption of peripheral release of
neurogenic inﬂammatory mediators (eg, glutamate, gene-related
peptide, substance P), which in turn reduces peripheral nociceptive
drive and peripheral sensitization, resulting in modiﬁed central pain
mediation. Inhibition of peripheral nociception in knee OA by intra-
articular (IA) injection of onabotA may be a new treatment modality.
This study aimed to evaluate the efﬁcacy of a single onabotA IA
injection in knee OA pain using traditional pain assessments (eg, daily
pain diary) and mechanistic, quantitative, experimental pain assess-
ment models to proﬁle peripheral and central actions. Safety data were
also collected.
Methods: Patients 40-75 y, with primary idiopathic knee OA and
Kellgren-Lawrence grade of I-III were enrolled in a 16-wk, double-
blind, placebo (PBO)-controlled study. Randomization was 1:1, strati-
ﬁed by 14-day baseline average daily worst pain (ADWP) score of 4.0-
9.0 (0-10 point numeric rating scale), to a single injection of ultra-
sound-guided IA onabotA (200 U) or PBO in the study knee. Primary
efﬁcacy endpoint was 14-day ADWP score change from baseline at wks
4, 8, and 12, jointly analyzed using repeated measures analysis of
covariance for between-group comparisons, adjusted for baseline
ADWP score; missing scores were imputed. 5 pain model evaluations
were conducted at baseline, day 1 pre-injection, and wks 4, 8, and 12:1) quantitative sensory testing of joint pain by pressure-pain threshold
(PPT) at 3 sites over the knee joint (3 cm medial, superior, or lateral to
edge of patella; 3-site average); 2) spreading sensitization testing by
PPT from the tibialis anterior muscle and ipsilateral extensor carpi
radialis longus muscle; 3) wind-up-like pain intensity (0-10 visual
analog scale) to experimental pressure pain stimuli using an automatic
pressure algometer to deliver 1 stimulus or 10 repeated stimuli (1 Hz)
over the tibialis anterior muscle and to the most painful site of the
study knee; 4) cuff algometry, which evaluated PPT via the mean of 3
measurements; 5) mapping of the total area of knee pain. Pain model
endpoints were analyzed using a Wilcoxon rank-sum test (calculated
by analysis of variance of ranked scores) without baseline covariate or
imputation.
Baseline Pain DETECT (PD-Q) scores were used post-hoc to classify
patients into pain subgroups of nociceptive (PD-Q12) or non-noci-
ceptive (13).
Results: Of 170 screened patients, 121 were randomized to onabotA
(n¼61) or PBO (n¼60); mean age 62.3 y, all Caucasian, and similar
numbers of men and women. No clinically relevant between-group
baseline differences were observed. The primary efﬁcacy analysis yiel-
ded no signiﬁcant difference between onabotA and PBO for the change
from baseline in ADWP score to the 3 time points (P¼0.70). Most pain
model tests showed no signiﬁcant difference at any time point. PPT in
the tibialis showed a trend toward improvement with onabotA at wks 4
(P¼0.08) and 8 (P¼0.07; Fig 1A). A similar trend was observed in wind-
up-like pain for the tibialis (wk 12, P¼0.13; Fig 1B). Posthoc analyses in
the 68 nociceptive pain patients showed signiﬁcant between-group
differences favoring onabotA for improved PPT over the tibialis at wks 4
(P¼0.03) and 8 (P¼0.02), with a trend at wk 12 (P¼0.13) and a trend for
the knee at wk 4 (P¼0.11; Fig 2A). A similar trend favoring onabotAwas
seen at wk 8 (P¼0.15) for wind-up-like pain at both tibialis and knee
(Fig 2B). The nociceptive subgroup also reported signiﬁcant pain relief
(P¼0.02; WOMAC pain score) favoring onabotA at wk 8, consistent with
a trend in daily worst pain intensity (P¼0.13).
Conclusion: This exploratory study found no signiﬁcant between-
group differences in the primary efﬁcacy endpoint. Pain model evalu-
ations indicated positive trends favoring onabotA. Post-hoc analyses in
the nociceptive subgroup showed that onabotA signiﬁcantly improved
outcomes in selected mechanistic pain models compared with PBO, in
parallel with reported pain relief. Mechanistic pain model evaluations
showed a larger trend of separation in both peripheral and spreading
pain (ie, central sensitization) than traditional clinical pain scores.
Disclosure: Funded by Allergan.39
RISK OF BIAS AND BRAND EXPLAIN THE OBSERVED INCONSISTENCY
IN TRIALS ON GLUCOSAMINE FOR OSTEOARTHRITIS:A META-
ANALYSIS OF PLACEBO-CONTROLLED TRIALS
P.R. Eriksen. The Parker Inst., Copenhagen, Denmark
Purpose: the aim of this study was to determine whether study
sponsor, chemical formulation, brand of glucosamine, and/or risk of bias
explain observed inconsistencies in trial ﬁndings of glucosamine’s
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thermore, we determined the effect of glucosamine on pain in OA and
how the aforementioned factors play a role in regards to the efﬁcacy of
the preparation on pain in OA.
Methods: A systematic review and stratiﬁed meta-analysis of
randomized placebo-controlled trials (RCTs) were conducted.
Inclusion criteria consisted of RCTs testing glucosamine compounds
vs. placebo in humans with combined treatment regimens as an
exclusion criterion (i.e. glucosamine combined with other inter-
vention vs. placebo). Random effects models were applied with
inconsistency (I-squared) and heterogeneity (Tau-squared) using
Review Manager and SAS, respectively. The major outcome measure
was reduction of pain. Selecting outcome-measuring scale for data
extraction was done after a predeﬁned veriﬁed hierarchy of pain
scales; the standardized mean difference (SMD and [95%CI]) served
as effect size.
Results: The inclusion criteria yielded 25 trials (3,458 patients). Com-
pared with a placebo, glucosamine reduced pain (SMD ¼ -0.51 [-0.72 to
-0.30]), although expected high level of between-trial inconsistency
was observed (I-sq¼88%). The single most important explanation (i.e.,
covariate) was brand (reducing heterogeneity by 41%, p¼(0.00032):
Twelve trials (1,437) using the RottapharmjMadaus product apparently
resulted in signiﬁcant pain reduction (-1.05 [-1.43 to -0.68],), with a
large amount of inconsistency(I-sq¼92%); whereas 13 trials (1,963
patients) using non-RottapharmjMadaus products consistently failed to
show a reduction in pain when compared with placebo (-0.11 [-0.46 to
0.24], I-sq¼10%) - Tau-sq reduced from 0.601 to 0.359 (p<0.001). The
second most important explanation was overall risk of bias (reducing
Tau-sq by 32%).
Conclusions: Trials using the RottapharmjMadaus glucosamine prod-
uct had a superior outcome on pain in OA compared to other prepara-
tions of glucosamine, though RottapharmjMadaus trial showed large
inconsistency in their results and therefore conﬁdence in the results in
limited. We did not ﬁnd an effect of other brands of glucosamine. Most
of the observed heterogeneity in trials on glucosamine for (OA) can be
explained by brand and risk of bias.Stratiﬁed meta-analysis
Variable Trials Effect
size
95%CI tau-squared p-value for
interaction
All trials 25 0.58 (0.90 to 0.26) 0.601
Label: 0.359 0.00032
Other label 13 0.11 (0.46 to 0.24)
Rottapharmj
Madaus
12 1.05 (1.43 to 0.68)
Chemical
structure:
0.5467 0.082
HCl 4 0.03 (0.72 to 0.77)
SO4 21 -0.7 (1.04 to 0.36)
Risk of bias
(overall)
0.4079 0.004
Low RoB 8 0.09 (0.54 to 0.36)
Unclear RoB 7 0.39 (0.90 to 0.12)
High RoB 10 1.14 (1.59 to 0.69)
Industry
funding
0.5499 0.0767
Yes 14 0.83 (0.41 to 1.24)
No 11 0.26 (0.73 to 0.20)
Figure 1. Chondrogenic potential of lenti-miR-im6 transduced BMSCs.
(A) Expression pattern of miR-im6 in presence of PTHrP for chondrogenic
differentiation. (B) Transduction efﬁciency of the produced miR-im6
lentivirus in BMSCs. (C) Ratio of GAG/DNA measured in cultured lentiviral
transduced pellets after 4 weeks of culture. The bars represent means 
SD. CM: BMSCs treated with their respective chondrogenic medium. CMT:
BMSCs treated with chondrogenic medium containing 5 ng/ml TGF-b.
CMTP: BMSCs treated with chondrogenic medium containing 5 ng/ml
TGF-b and 100 ng/ml PTHrP (D and F) Gross appearances and Safranin-O
staining of each chondrogenic pellet. (E) Protein expression of chondro-
genic differentiation and hypertrophic markers in the lentiviral trans-
duced pellets. Detection of type II collagen, SOX9, ALP, and type X collagen40
TRANSCRIPTION FACTOR SPB-X IS A KEY MOLECULE INDUCING
HYPERTROPHY OF DIFFERENTIATED CHONDROCYTE FROM MSC
G.-I. Im, J.-M. Lee, J.-M. Ahn, E.-A. Kim. Dongguk Univ. Ilsan Hosp.,
Goyang, REPUBLIC OF.KOREA
Purpose: To investigate that novel microRNA, miR-im6 can increase the
chondrogenic potential and inhibit the hypertrophy of BMSC through
down-regulation of transcription factor SPB-X.
Methods: Chondrogenesis of PTHrP-treated BMSCs: To induce chon-
drogenesis, in vitro pellet cultures were carried out using 2.5 105 cells
BMSCs at passage 3 in chondrogenic medium (CM); 10 ng/ml of TGF-b3
was also added for CM. From the 14th day of culture, subsets of pellets
were additionally treated with 100 ng/ml PTHrP, and after two furtherweeks of in vitro culture in their respective media, pellets were har-
vested for analysis.
Lenti-viral transduction: Lenti-viral transduction was performed by
infection of miR-im6 virus supernatant (MOI¼10) for 7 hrs on BMSCs at
passage 3. And then, they were induced chondrogenesis in the presence
of TGF-b3 for 4 weeks. Chondrogenic potentials of each pellet were
evaluated using Rq-PCR and Western blotting.
3’-UTR luciferase activity analysis: We constructed luciferase reporter
vectors harboring wild type andmutated 3’UTR of miR-im6 target genes
(SPB-X and WNT6). Luciferase reporter gene expression was inves-
tigated in Hela cell line transfected with 50 nM negative or miR-im6
mimic. Hela cells were co-transfected with each reporter vectors and
miR-im6-mimic for 24hr. And then, their proteins were extracted with
cell lysis buffer and luciferase activities were detected with
luminometer.
Analysis of chondrogenic potentials of MSC derived from SPB-X K/O
mouse: Mouse MSCs were isolated from wild type and SPB-X K/O
mouse, respectively. After their chondrogenic induction, the expression
of hedgehog related signals was compared with each other.
Results: Overexpression of miR-im6 enhances the chondrogenic
potential and inhibits hypertrophy of hBMSCs: Amount of GAG/DNA
measured in cultured lentiviral transduced pellets after 4 weeks of
culture. GAG/DNA content of lenti-miR-im6 transduced hBMSCs was
higher than other groups in treatment of TGF-b (Fig 2c). In safranin-O
staining of each chondrogenic hBMSC pellet, staining intensity of lenti-
miR-im6 transduced hBMSCs was also stronger than TGF-b treated
positive control, like PTHrP-treated positive control (Fig 2f). These
results were conﬁrmed because overexpression of miR-im6 in chon-
drogenic induction of hBMSCs enhances the expressions of chondro-
genic markers (Type II collagen, SOX9) and suppress the expression of
hypertrophic markers (ALP, Type X collagen) (Fig 2e).
MiR-im6 inhibits major molecules of hedgehog signal and wnt
signal pathway: We conﬁrmed mRNA and protein levels using Rq-PCR
and Western blotting when miR-im6 was overexpressed in hBMSCs
chondrogenic pellets after 4 weeks. Rq-PCR results show that Ihh and
ptch1 initiating hedgehog signal pathway were down regulated with
SPB-X, simultaneously (Fig 2a). Their protein levels were decreased inat 4 week after chondrogenic differentiation using Western blotting.
